NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $25.92 +0.43 (+1.69%) Closing price 07/15/2026 04:00 PM EasternExtended Trading$25.78 -0.14 (-0.54%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$25.18▼$26.0850-Day Range$20.48▼$26.4152-Week Range$19.69▼$28.35Volume1.27 million shsAverage Volume1.78 million shsMarket Capitalization$4.44 billionP/E Ratio11.78Dividend YieldN/APrice Target$32.94Consensus RatingModerate Buy Company Overview ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics. The company’s flagship product, NUPLAZID® (pimavanserin), received U.S. Food and Drug Administration approval for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Beyond NUPLAZID, ACADIA is pursuing additional indications for pimavanserin in dementia-related psychosis and Alzheimer’s disease psychosis, as well as exploring novel candidates for schizophrenia and other neuropsychiatric disorders. These efforts are complemented by strategic collaborations, translational research initiatives, and robust clinical trial programs to expand the company’s impact on patient care. ACADIA serves patients and healthcare providers primarily in North America, with ongoing clinical studies and regulatory submissions extending into Europe and Asia-Pacific regions. The company leverages partnerships with academic institutions and industry collaborators to accelerate development timelines and enhance its global footprint. Guided by a leadership team with extensive experience in CNS drug development, ACADIA continues to build on its scientific heritage and commitment to delivering differentiated therapies for complex neurological conditions.AI Generated. May Contain Errors. Read More ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 25th out of 1,702 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on no strong buy ratings, 12 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialACADIA Pharmaceuticals has a consensus price target of $32.94, representing about 27.1% upside from its current price of $25.92.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth132.43% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 132.43% in the coming year, from $0.37 to $0.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 11.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.96.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 11.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.07.Price to Earnings Growth RatioACADIA Pharmaceuticals has a PEG Ratio of 18.36. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.67% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 4.75.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 7.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.21 News SentimentACADIA Pharmaceuticals has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for ACADIA Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest10 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat Follows3 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $219,813.00 in company stock.Percentage Held by Insiders26.20% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACAD Stock News HeadlinesAcadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026July 15 at 5:35 PM | finance.yahoo.comAcadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026July 15 at 4:05 PM | businesswire.comThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 years of trading experience, one chart detail stands out above all others as the primary signal before entering any trade. The Ultimate Day Trading Cheatsheet distills that edge into 7 pages, including 23 Golden Rules and a specific trade setup with a reported 94.2% win rate. It's available at no cost.July 16 at 1:00 AM | The TradingPub (Ad)An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?July 11, 2026 | fool.comACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value?July 10, 2026 | finance.yahoo.comHow CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) InvestorsJuly 10, 2026 | finance.yahoo.comIs ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?July 10, 2026 | finance.yahoo.comVerastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?July 10, 2026 | finance.yahoo.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $26.71 on January 1st, 2026. Since then, ACAD shares have decreased by 3.0% and is now trading at $25.92. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by $0.02. ACADIA Pharmaceuticals's quarterly revenue was up 9.7% compared to the same quarter last year. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? Top institutional investors of ACADIA Pharmaceuticals include Hennion & Walsh Asset Management Inc. (0.06%), Handelsbanken Fonder AB (0.04%), Gradient Investments LLC (0.02%) and Assenagon Asset Management S.A. (0.01%). Insiders that own company stock include Stephen Davis, Mark C Schneyer, Brendan Teehan, Austin D Kim, Elizabeth A Garofalo, James Kihara, Laura Brege, Jennifer J Rhodes and James M Daly. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/06/2026Today7/16/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 3 weeks, ACAD's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year Founded1993Price Target and Rating Average Price Target for ACADIA Pharmaceuticals$32.94 High Price Target$40.00 Low Price Target$17.00 Potential Upside/Downside+27.1%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$2.20 Trailing P/E Ratio11.78 Forward P/E Ratio70.05 P/E Growth18.36Net Income$391 million Net Margins34.30% Pretax Margin10.51% Return on Equity9.61% Return on Assets7.07% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.48 Sales & Book Value Annual Sales$1.07 billion Price / Sales4.14 Cash Flow$0.90 per share Price / Cash Flow28.73 Book Value$7.25 per share Price / Book3.58Miscellaneous Outstanding Shares171,240,000Free Float126,372,000Market Cap$4.44 billion OptionableOptionable Beta0.80 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ACAD) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe window is closingWe printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...American Alternative | SponsoredUnder $1 while the market panicsPresident Trump just called on the Senate to pass the CLARITY Act “in honor” of the late Senator Lindsey Graha...Crypto 101 Media | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThis Is How Financial Freedom Dies—And Most People Never See It ComingWhile the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
